Kineta could receive more than $359 million as a result of the deal.
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta’s existing target therapy into a medicine that treats nerve pain.
“There is a tremendous unmet patient need to develop more effective, safer and nonaddictive therapies for the many people who suffer from chronic pain,” Kineta CEO Shawn Iadonato said in a statement Monday.
The Seattle company will be eligible to receive up to $359 million as part of the deal, in addition to an undisclosed upfront payment. It could also receive royalties on eventual sales of products that result from the deal.
Most Read Business Stories
- Hunts Point mansion, famous for huge art collection, sells for record $37.5 million WATCH
- Protecting your Internet accounts keeps getting easier. Here’s how to do it.
- Renter boom: Apartments filling up faster in Seattle area than anywhere in the U.S.
- Boeing's quarterly report will give first look at financial impact of MAX crisis
- Medicare, Social Security face shaky fiscal futures